Analysis of data from the TCGA database revealed that APOC2 is significantly upregulated in multiple tumor types, including clear cell renal cell carcinoma (ccRCC), bladder urothelial carcinoma, colorectal cancer, breast cancer, and esophageal carcinoma (Figure 1A). Here, APOC2 is linked to bladder transitional cell carcinoma.